Continued Efgartigimod Treatment in Adults With Ocular Myasthenia Gravis Linked to Further Symptom Improvement
KEY TAKEAWAYS
- In phase 3 data from the ADAPT OCULUS study, participants with ocular myasthenia gravis treated with additional cycles of subcutaneous efgartigimod beyond the placebo-controlled period showed continued improvement in symptoms.
- Mean patient-reported ocular MGII scores improved from –4.5 to –6.8 points in AChR+ participants and from –2.7 to –4.5 points in triple-seronegative participants.
- These findings from ADAPT OCULUS were presented at AANEM 2026.
Additional subcutaneous treatment cycles with Vyvgart (efgartigimod alfa-fcab; argenx, Boston, MA) beyond the placebo-controlled period were associated with continued improvement in symptoms for participants with ocular myasthenia gravis (MG) in the phase 3 ADAPT OCULUS clinical trial (NCT06558279). The findings, presented at the 2026 American Association of Neuromuscular & Electrodiagnostic Medicine (AANEM) Annual Meeting, extend the previously reported placebo-controlled results by examining how ocular symptoms changed with further treatment.
ADAPT OCULUS is a phase 3, randomized, double-blind study evaluating subcutaneous efgartigimod PH20 in adults with ocular MG. The study includes participants who are acetylcholine receptor antibody positive (AChR+) as well as those who are triple seronegative. The Myasthenia Gravis Impairment Index (MGII) patient-reported ocular score was used to assess ocular impairment, an outcome highlighted during an argenx-sponsored scientific presentation at AANEM.
What the AANEM Data Showed
- After 2 additional treatment cycles beyond the placebo-controlled period, mean MGII patient-reported ocular scores improved from –4.5 to –6.8 points among AChR+ participants.
- Among triple-seronegative participants, mean scores improved from –2.7 to –4.5 points with additional treatment.
- Separate analyses presented at AANEM examined the clinical meaningfulness of changes on the MGII patient-reported ocular score, including patient perspectives on meaningful changes in ocular symptoms.
What This Could Mean in Clinical Practice
For neurologists treating patients with ocular MG, the new analysis addresses a question beyond the initial treatment response: whether improvement can continue as patients receive additional Vyvgart cycles. The findings are particularly relevant because the study includes participants across antibody-defined subgroups and focuses specifically on ocular symptoms using a patient-reported outcome measure. However, the longer-term results should be interpreted within the design of the ongoing ADAPT OCULUS program. They do not establish the optimal duration or number of treatment cycles, nor do they support the assumption that individual patients will experience progressively greater improvement with each cycle.
Vyvgart and Vyvgart Hytrulo (efgartigimod alfa and hyaluronidase-qvfc; argenx, Boston, MA) are approved for the treatment of adults with generalized MG, while Vyvgart Hytrulo is also approved for the treatment of people with chronic inflammatory demyelinating polyneuropathy. Ocular MG is not currently an approved indication.
Source
- Howard JF Jr, Seth A, Karam C. Investigating the Therapeutic Potential of Targeting FcRn- and Complement-Mediated Pathways in Autoimmune Diseases. Industry Forum presented at: American Association of Neuromuscular & Electrodiagnostic Medicine (AANEM) 2026 Annual Meeting; September 29, 2026; Orlando, FL. Sponsored by argenx.
- argenx. argenx Presents New Data at AANEM and MGFA Scientific Session Showcasing Earlier and Sustained Treatment in MG and CIDP with VYVGART and Progress Across its Neuromuscular Pipeline. Press release. September 29, 2026.